These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6143506)

  • 21. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
    Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
    Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of gender differences in neuroleptic response in patients with schizophrenia.
    Pinals DA; Malhotra AK; Missar CD; Pickar D; Breier A
    Schizophr Res; 1996 Dec; 22(3):215-22. PubMed ID: 9000318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroleptic dose reduction in older psychotic patients.
    Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
    Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis.
    Weinberger DR; Bigelow LB; Klein ST; Wyatt RJ
    J Clin Psychopharmacol; 1981 May; 1(3):120-3. PubMed ID: 6117582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
    Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
    Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
    Hunt JI; Singh H; Simpson GM
    J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
    Woggon B; Bickel P; Schnyder B
    Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
    Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
    Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylphenidate augmentation therapy in schizophrenia.
    Carpenter MD; Winsberg BG; Camus LA
    J Clin Psychopharmacol; 1992 Aug; 12(4):273-5. PubMed ID: 1527231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
    Manos N; Lavrentiadis G; Gkiouzepas J
    J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome study of first-episode psychosis. I: Relapse rates after 1 year.
    Rabiner CJ; Wegner JT; Kane JM
    Am J Psychiatry; 1986 Sep; 143(9):1155-8. PubMed ID: 2875663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
    Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic principles for differential therapy of psychoses].
    Hell D; Bridler R
    Praxis (Bern 1994); 2001 May; 90(22):975-80. PubMed ID: 11450185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Algorithm for the treatment of acute psychotic episodes.
    Hayashida M; Nakane Y
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S3-7. PubMed ID: 10560890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
    Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
    Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.